Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 42

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
ulgated under the Securities Act of 1933, as amended (the “Securities
Act”).

H.C. Wainwright & Co., LLC (the “Placement
Agent”) acted as our exclusive placement agent in connection with the offering. Pursuant to the terms of the placement agent agreement,
we paid the Placement Agent a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the offering and a management
fee equal to 1.0% of the aggregate gross cash proceeds in the offering. In addition, we paid for certain non-accountable expenses in the
amount of $15,000 and a clearing fee in the amount of $10,000. We also issued to the Placement Agent (or its designees) warrants to purchase
up to 15,325 shares of common stock (the “January 2025 Placement Agent Warrants”). The January 2025 Placement Agent Warrants
have an exercise price equal to $6.382 per share and are exercisable upon issuance and expire twenty-four months from the date of issuance.

24

The registered direct offering and the concurrent
private placement (collectively, the “January 2025 Offering”) closed on January 30, 2025, resulting in net proceeds of approximately
$804,346, after deducting estimated offering expenses paid by us, including the Placement Agent fees.

Pursuant to the January 2025 Securities Purchase
Agreement, within 45 days from the date of the January 2025 Securities Purchase Agreement, we were required to file a registration statement
with the SEC providing for the resale by the January 2025 Purchasers of the shares of common stock issuable upon exercise of the January
2025 Warrants. The registration statement was declared effective by the SEC on April 2, 2025. The Company shall use commercially reasonable
efforts to keep such registration statement effective at all times until no January 2025 Purchaser owns any January 2025 Warrants or shares
underlying the January 2025 Warrants issuable upon exercise thereof.

February 2025 Offering

On February 5, 2025, we entered into a securities
purchase agreement (the “February 2025 Securities Purchase Agreement”) with certain institutional investors (the “February
2025 Purchasers”) pursuant to which we sold an aggregate of 300,700 shares of common stock at a purchase price of $3.575 per share
in a registered direct offering priced at-the-market